The screening of kinase inhibitors is crucial for better understanding properties of a drug and for the identification of potentially new targets with clinical implications. Several methodologies have been reported to accomplish such screening. However, each has its own limitations (e.g., the screening of only ATP analogues, restriction to using purified kinase domains, significant costs associated with testing more than a few kinases at a time, and lack of flexibility in screening protein kinases with novel mutations). Here, a new protocol that overcomes some of these limitations and can be used for the unbiased screening of kinase inhibitors is presented. A strength of this method is its ability to compare the activity of kinase inhibitors across multiple proteins, either between different kinases or different variants of the same kinase. Self-assembled protein microarrays generated through the expression of protein kinases by a human-based in vitro transcription and translation system (IVTT) are employed. The proteins displayed on the microarray are active, allowing for measurement of the effects of kinase inhibitors. The following procedure describes the protocol steps in detail, from the microarray generation and screening to the data analysis.
Introduction
Protein kinases are responsible for the phosphorylation of their targets and can modulate complex molecular pathways that control many cellular functions (i.e., cell proliferation, differentiation, cell death and survival). Deregulation of kinase activity is associated with more than 400 diseases, making kinase inhibitors one of the main classes of drugs available for treatment of several diseases, including cancer, cardiovascular and neurological disorders as well as inflammatory and autoimmune diseases 1, 2, 3 .
With the advent of precision medicine, the identification of new therapies, especially kinase inhibitors, have great appeal pharmaceutically and clinically. Several approaches can be used for the identification of possible new pairs of kinase/kinase inhibitors, including the de novo design of kinase inhibitors and identification of new targets for existing FDA-approved drugs. The latter is especially attractive, since the time and money required to implement these drugs in clinics are drastically reduced due to the availability of previous clinical trial data. A canonical example of the repurposing of a kinase inhibitor is imatinib, initially designed for the treatment of chronic myelogenous leukemia (CML) through the inhibition of BCR-Abl, which can also be successfully used for the treatment of c-Kit over-expressing gastrointestinal stromal tumors (GISTs) 4, 5, 6, 7 .
The screening of kinase inhibitors can be performed in binding assays or enzymatic-based assays. The first class of assays focuses on proteindrug interactions and can provide information such as ligation site and affinity. Since the activity of the kinase at the time of these assays is unknown, a number of interactions may be missed or falsely identified due to conformational changes in the protein. On the other hand, enzymatic-based assays require the protein kinases to be active and provide valuable information regarding the inhibitor's effect on enzyme activity, however, this type of screening is generally more time consuming and expensive. Currently, both types of assays are commercially available from several sources. They represent a reliable option for the screening of kinase inhibitors with a few limitations, including: I) most of the methods involve testing of multiple kinases individually, which can make the screening of a large set of proteins costly; II) the set of kinases to be tested is limited to a list of preselected, wild-type kinases and several well-known mutated versions of some kinases, hindering the testing of many new mutated isoforms.
In this context, protein microarrays are a powerful platform capable of overcoming some of the limitations presented by commercially available techniques. It is suitable to perform enzymatic-based assays in high-throughput screening using full-length, active proteins of any sequence of interest. The microarrays can be generated by a self-assembled approach like NAPPA (nucleic acid programmable protein array), in which proteins are expressed just in time for the assays, increasing the likelihood that those displayed on the array are indeed active. The proteins displayed on NAPPA are produced using human-derived ribosomes and chaperone proteins in order to improve the likelihood of natural folding and activity.
Array sample preparation
1. Resuspend the DNA pellet from the in-house mini-prep (step 2.3.6) in 20 µL of ultrapure water and shake at 1,000 rpm for 2 h. For midi/max prep DNA, dilute each sample to a final concentration of 1.5 µg/µL and transfer 20 µL to an 800 µL collection plate. 2. Prepare printing mix. For one 96 well plate, prepare 1 mL of printing mix [237.5 µL of ultrapure water; 500 µL of poly-lysine (0.01%); 187.5 µL of BS3 (bis-sulfosuccinimidyl, 50 mg/mL in DMSO); and 75 µL of polyclonal anti-flag rabbit antibody)]. NOTE: The chemicals should be added in the specified order to avoid precipitation. 3. Add 10 µL of printing mix to each sample, seal plates with aluminum foil, and shake at RT for 90 min at 1,000 rpm. Store the plates overnight (~16 h) at 4 °C. 4. On the printing day, briefly vortex and spin the plates. Transfer 28 µL of each sample to a 384 array plate. This transfer can be done using automation or a multi-channel pipette. It is crucial to keep track of the position of the samples in the 384 array plate. 5. Spin the plate down briefly to remove any bubbles. Seal the plates with foil.
Generation of NAPPA arrays: microarray printing
NOTE: All the printing conditions were optimized for the instrument listed in Table of Equipment and Materials. If using a different array, further optimization may be required.
1. Arrayer clean up. Before starting, empty all waste tanks and refill the reservoirs with ultrapure water or 80% ethanol, if needed. Clean pins one-by-one with lint-free wipes and ultrapure water. Dry the pins with lint free wipes and carefully place them back into the arrayer head. 
Detection of proteins on NAPPA arrays
1. Add primary antibody. Remove the slides from the blocking solution (step 7.5) and gently dry the back side (non-printed side) using a paper towel. Place the slides on a support and apply 600 µL of primary antibody (mouse anti-flag) diluted 1:200 in 1x TBST + 5% milk. Incubate for 1 h at RT. 2. Wash the slides with 1x TBST + 5% milk on a rocking shaker (3x for 5 min each). 3. Add secondary antibody. Remove the slides from the washing solution and gently dry the back side using paper towel. Place the slides on a support and apply 600 µL of secondary antibody (cy3-labbeled anti-mouse antibody) diluted 1:200 in 1x TBST + 5% milk. Protect the slides from light and incubate for 1 h at RT. 4. Wash the slides with 1x TBST on a rocking shaker (3x for 5 min each). Quickly rinse the slides with ultrapure water and dry using pressured air. Proceed with the scanning (section 11).
Tyrosine kinase inhibitor screening on NAPPA arrays
NOTE: Multiple slides can be processed in the same experiment, however, make sure that in each step, one slide is processed at a time and that they do not dry between steps. Add all solutions to the non-label or non-specimen end of the slide.
2. Perform the phosphatase and DNase treatment. Remove slides from the blocking solution (step 7.5) and gently dry the backside using paper towel. Place the slides on support and apply 200 µL of phosphatase/DNase solution. Place a microarray coverslip to avoid evaporation. Incubate at 30 °C for 45 min in the oven. 3. Phosphatase and DNase treatment II: remove arrays from the oven, discard the coverslip, remove excess solution, and apply 200 µL of freshly made phosphatase and DNase solution. Cover microarrays with coverslip and incubate for another 45 min at 30 °C in the oven. 4. Wash slides with 1x TBST + 0.2 M NaCl on a rocking shaker (3x for 5 min each). 5. Perform the drug treatment and kinase reaction. Remove slides from the washing solution and gently dry the backside using a paper towel.
Place the slides on support and apply 200 µL of drug/kinase solution. Place a coverslip on top to avoid evaporation. Incubate for 1 h at 30 °C in the oven. 6. Wash slides with 1x TBST + 0.2 M NaCl on a rocking shaker (3x for 5 min each). 7. Repeat steps 8.1-8.4 using as primary antibody anti-phosho-Tyr antibody diluted 1:100. Replace 1x TBST + 5% milk in all steps with 1x TBST + 3% BSA.
Automated hybridization protocol
NOTE: Alternatively, a hybridization station can be used to automate all hybridizations and washes on the NAPPA arrays (sections 7-9) and the protocol is provided as Supplementary File 1.
Image acquisition
NOTE: Microarray images should be acquired at a resolution of 20 microns or higher.
1. Load microarrays into the slide holder magazine with the proteins facing up. Load the magazine into the microarray scanner. 2. Select the green laser with a 575/30 nm emission filter to scan the signal from the cy-3 labelled secondary antibody. If a different fluorophore is used, select the correct laser/wavelength to detect the signal from the fluorescent dye. 3. Define the name for each image and the location that they will be saved. 4. (Optional): for each new fluorophore, optimization of the scanning conditions are recommended to detect the linear range of the signal intensity. To do so, scan a microarray using a range of photomultiplier (PMT) and gain until a clear image is obtained with non-saturated signal and low background. 5. Scan all microarrays with the optimized settings and remember to turn the autogain off.
NOTE: For data analysis, all microarrays should be scanned using the same scanning settings. For kinase assays using cy3 as a fluorophore, the images are scanned with a 20% PMT, laser intensity of 25%, and 10 microns of resolution, using the scanner listed in the 
Data processing and analysis
NOTE: Several software packages are available for the quantification of microarray data with similar capabilities. The procedure described here was designed for the software listed in the Table of Equipment and Materials. 1. Load the TIFF files to be quantified, design the grid to match the microarray layout and adjust the size of the spots to incorporate the entire signal with the minimum area possible. Neighboring spots should not overlap. Visually inspect how well the software is performing and adjust the grid manually, if necessary. 2. Quantify the signal intensity of the microarray. Visually inspect the spots for any abnormality (non-specific binding, dust, etc.) and remove them from the data analysis. 3. Correct the background locally using the signal of neighboring areas on the array in which no spot is present. 4. Normalize data. To compare the signal across different arrays, the signal intensity of each microarray must be normalized. To exclude any outliers, normalize the data using the trimmed mean 30% of the signal from the positive control (IgG spots) of the dephosphorylated microarrays. NOTE: The signal from the IgG spot does not change during the phosphorylation and dephosphorylation of the microarrays and is suitable for the normalization. 5. Identify active kinases. For each feature displayed on the microarray, calculate the ratio between the normalized signal intensity in the autophosphorylated and dephosphorylated arrays. Set a threshold of 1.5-fold change for the identification of the active kinases and mark all the other features as unable to undergo autophosphorylation (N/A). 6. Calculate the activity of each kinase identified in step 12.5 as a percentage of adjusted signal (signal intensity of the normalized positive control array (DMSO) subtracted by the signal intensity of the normalized negative control array (dephosphorylated).
Representative Results
Self-assembled NAPPA microarrays provide a solid platform that can been used for many distinct applications, including biomarker discovery, protein-protein interactions, substrate identification, and drug screening 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 .
The overall methodology adopted for the study of kinase activity and screening of tyrosine kinases inhibitors on NAPPA microarrays is schematically represented in Figure 1 . First, NAPPA microarrays are generated by the immobilization of cDNA and capture agent onto the coated microarrays. The cDNAs are then used as a template for the transcription and translation of proteins, using a human-based IVTT system, and the newly synthesized proteins are immobilized by the capture agent The next step is the autophosphorylation reaction, in which microarrays are incubated with kinase buffer in the absence of ATP (negative control array, referred to as dephosphorylated microarrays), and kinase buffer is supplemented with ATP (positive control, referred to as autophosphorylated arrays) or ATP + DMSO (vehicle control). It should be emphasized that during this step, no kinase is added; therefore, the intrinsic activity of each kinase displayed on the microarray is quantified through measurement of its phosphorylation levels using a pan antiphospho-tyrosine antibody followed by a cy3-labbeled secondary antibody (Figure 1) .
Quality control of the NAPPA-kinase arrays displaying a panel of human protein kinases printed in quadruplicate is shown in Figure 2 . The levels of immobilized DNA were measured by DNA staining and it showed an even signal across the microarray, suggesting the amount of DNA printed on the array was uniform. It is also possible to observe several features without any DNA staining. These features correspond to some controls in which DNA was omitted from the printing mix [i.e., empty spots (nothing was printed), water spots, purified IgG spot (poly-lysine, crosslinker and purified IgG), printing mix only (complete printing mix: poly-lysine plus crosslinker and anti-flag antibody, without any DNA)]. The levels of protein displayed on the NAPPA-kinase microarrays were assessed after the IVTT reaction using anti-tag antibody.
For the kinase screening, Flag was used as the tag of choice and the level of protein displayed on the microarray was measured using an antiflag antibody. As shown, the majority of spots containing cDNA successfully displayed detectable levels of protein. Some of the control spots without cDNA also revealed signal with the anti-flag antibody: IgG spot (used to detect the activity of the secondary antibody) and empty vector spots (cDNA codes for the tag only) (Figure 2) . NAPPA-kinase microarrays showed good reproducibility among slides, with the correlation of the levels of protein display among distinct printing batches higher than 0.88 ( Figure 2 ). Within the same batch the correlation was even higher, close to 0.92 (data not shown).
Next, the kinase autophosphorylation activity of the proteins displayed on the array was measured using anti-phospho-tyrosine antibody (Figure 3) . Protein displayed on the array showed high levels of protein phosphorylation after expression (Figure 3, left) , which may be caused by intrinsic kinase activity of the protein displayed on the array or by active kinases present in the IVTT mix. This phosphorylation was completely removed with lambda phosphatase treatment and these microarrays were used for the kinase assays. After dephosphorylation, autophosphorylation reactions performed without ATP showed no significant levels of phosphorylation, as expected, while microarrays incubated with kinase buffer in the presence of ATP showed protein phosphorylation as fast as 15 min (Figure 3) . For the drug screening, the kinase activity was measured after 60 min of autophosphorylation reaction to maximize the number of kinases tested.
The comparison between microarrays in which the phosphorylation levels were measured right after protein expression (Figure 3 , left) and after 60 min of autophosphorylation reaction (Figure 3 , right) showed: i) proteins phosphorylated only after expression, suggesting they can be exogenously phosphorylated by proteins present on the IVTT mix, but cannot be autophosphorylated; ii) protein phosphorylated only after the autophosphorylation reaction, suggesting these proteins were not active after protein expression and required co-factors present in the kinase buffer to be active; or iii) protein phosphorylated on both arrays, suggesting they were active in both settings (Figure 3) .
As an example of the results obtained for the screening of tyrosine kinase inhibitors on NAPPA-kinase arrays three kinases inhibitors with distinct selectivity across protein kinases were used: staurosporine, imatinib and ibrutinib. For all screenings, dephosphorylated NAPPA microarrays were incubated with increasing concentrations of TKI (ranging from 100 nM to 10 uM) during the autophosphorylation reaction. The first TKI tested was staurosporine, a global protein kinase inhibitor, that showed potent kinase inhibition on the microarray across virtually all kinases tested 11 .
Next, imatinib was tested, an ABL and c-Kit inhibitor used for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors 4, 5, 6, 7 . On NAPPA-kinase arrays imatinib showed a significant reduction in Abl1 and BCR-Abl1 activity whereas other kinases remained mostly unaffected (Figure 4A) . The data quantification for the kinase activity was normalized against the dephosphorylated array and represented as a percentage of the positive control microarray (vehicle only). Data for TNK2 (non-relevant kinase), Abl1 and BCR-Abl1 is shown in Figure 4B . As expected, imatinib showed selective inhibition towards Abl1 and BCR-ABl1. The data for c-Kit was inconclusive due to lack of activity on the positive control arrays.
Finally, ibrutinib, an FDA-approved covalent inhibitor of Bruton's tyrosine kinase (BTK), was tested. Ibrutinib is currently used in the treatment of several blood-related cancers with overactive BTK, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström's macroglobulinemia 21, 22 . Figure 4C , is representative of typical results obtained for the ibrutinib screening. The kinase activity of ABL1 (nonrelevant kinase) and BTK (canonical target) and ERBB4 (potential new target) is shown in Figure 4D . The data suggests ERBB4 can be inhibited by ibrutinib in a dose specific fashion. This inhibition was confirmed in vitro and in cell-based assays 11 , demonstrating the power of this platform. During the optimization phase of the study of kinase activity on NAPPA arrays, one of the main sources of background and low dynamic range observed was the BSA used on the printing mix. BSA was providing the primary amines necessary for crosslinking with the aminosilane surface and was trapping the DNA and the capture antibody on the spot. However, BSA is highly phosphorylated, making it difficult for the detection of the autophosphorylation signal on the array above the background noise. To solve this problem, several alternatives for BSA in the printing mix were tested, and poly-lysine was identified as good substitute. Poly-lysine lacks any phosphorylation site; therefore, the background from nonexpressed arrays is very minimal. Moreover, microarrays printed with poly-lysine are reproducible and display good levels of proteins (Figure 2) .
The next critical modification performed on the standard NAPPA assay was the addition of a Phosphatase/DNase treatment step. The treatment of the microarrays with phosphatase allows the removal of any phosphorylation that occurred in the IVTT mix during protein synthesis and capture (Figure 3) . The source of this phosphorylation could be from intrinsic autophosphorylation activity or from the activity of kinases present in the IVTT mix. The removal of all phosphorylation post-expression allowed easy identification of the kinases that are active and can undergo autophosphorylation (Figure 3) .
Critical steps within the protocol NAPPA is a robust technology, but as expected, there are several critical steps. The first is the acquisition of high quality DNA in the appropriate concentration. Using DNA of poor quality or in low concentrations will generate poor quality microarrays with several features not being expressed and displayed in the appropriate levels, decreasing the number of proteins analyzed on the array. The second critical step is the expression of proteins on the microarray. The use of an IVTT system that will express high levels of functional protein is vital for studying kinase activity on the array.
The next critical step on the TKI screening is how the microarrays are handled. The microarrays should not dry during any step of the protocol, and gentle handling is recommended to prevent scratches that can increase the background signal. Since the arrays from the entire experiment will be compared against each other, it is important to assure that every incubation step is even across all slides. For example, the time required to perform one step in a single array should be taken into consideration when a batch of 20 arrays is processed to prevent differences in the length of incubation across arrays.
Finally, design of the experiment and the inclusion of both positive and negative controls are critical for quality control and data analysis. The first set of controls are those printed in each array and includes negative controls [i.e., empty spots (without any material printed), water or empty vector (express only the tag)], as well as a positive control (i.e., purified IgG, that is detected by the secondary antibody and is inert to alteration in the phosphorylation levels). Collectively, they measure the background levels of the microarray, possible carryover during printing and the signal intensity of the detection method.
The next set of controls are the drug screening controls and include the dephosphorylated and autophosphorylated microarrays (in the presence or absence of DMSO). As mentioned earlier, the dephosphorylated microarray measures the level of phosphorylation after phosphatase treatment and therefore the baseline level for all other experiments. The lower the baseline level is, the higher the dynamic range of the assays. The autophosphorylated arrays present the maximum phosphorylation levels of all arrays and the signal should be strong and clear. It is used for data analysis, but also as a control that all reactions were performed successfully on the array.
Limitations of the technique
As of now, one of the limitations of the drug screening presented here is its ability to screen only protein kinases that can be autophosphorylated. One possible way to overcome this is to print a kinase and known substrate in the same spot. Co-printing of DNA for two distinct proteins was successfully accomplished 15 , suggesting the feasibility of this approach. Moreover, the protein displayed on the array might not be folded correctly resulting in an inactive protein. The use of human-based expression system made a significant improvement in the kinase activity measured on the array; however, some proteins still cannot be analyzed on the array due to its inactivity.
A second limitation is the measurement of the phosphorylation using a pan anti-phospho-tyr antibody. Despite its non-specificity regarding the motif of the phosphorylation site, all measured phosphorylations occurred on tyrosine residues, leaving behind serines and threonines and their respective kinases. To date, more than 10 pan phospho-Ser/Thr antibodies have been tested without success, despite several attempts to optimize incubation and washing conditions. A new detection system that is independent of antibodies may be the best option to expand the number of protein kinases that can be screened for drug inhibition. In this context, a few options are available including radioactivity or chemical approaches like click conjugation. A series of optimizations are required to minimize the background signal and provide a good dynamic range for the assays.
The third limitation is the acquisition of cDNA clones to be printed on the array. The cDNA clones can be generated using any cloning technique including site-specific recombination systems, such as Creator or Gateway 23 . Another option is to purchase the clones from the DNAsu library, found at <https://dnasu.org/DNASU/Home.do>, where more than 17,000 cDNAs clones, including the entire human kinome, is readily available to be used for the construction of NAPPA arrays 24 .
The fourth limitation is that not every laboratory is equipped with appropriate equipment to fabricate and screen their own NAPPA arrays. This protocol provides alternative methods to generate the DNA to be printed on the microarray, without the need of high-throughput equipment, and protocols to manually perform all the hybridization steps. However, access to an arrayer and microarray scanner is still necessary. One option to overcome this issue is to use the NAPPA core service and facility, found at <http://nappaproteinarray.org/>, which distributes customized NAPPA microarrays at a non-profit academic price. Finally, as of any screening methodology, the data obtained on the arrays are susceptible to be artefacts (either positive or negative) and therefore should be validated using orthogonal assays.
Significance with respect to existing methods Several platforms are available commercially for the screening of protein kinases. One approach routinely used is binding assays, which can be performed with protein fragments, kinase domain, larger protein fragments with the kinase domain and some regulatory regions, and even full-length proteins. The proteins are usually expressed in bacterial systems due to the cost and simplicity in the expression and purification protocols. The interaction between the drug of interest and the protein is then measured with some type of report assay like fluorescence or presence of tags, for example. The main limitation of this set of approaches is the fact that the protein is not necessarily active during the Copyright © 2019 Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License October 2019 | 152 | e59886 | Page 10 of 11 interaction with the drug, which may result in the identification of false positive and false negative interactions. Protein fragments are particularly vulnerable to changes in the conformation and lack of activity and all the data obtained should be validated using active proteins, preferably in their full-length form. Another limitation of some of the platforms is the capability to screen only ATP analogs, limiting its overall use.
Most of the commercially available services for the screening of TKIs using enzymatic based approaches utilize only wild type versions of the kinase of interest, and sometimes only a selected few mutants. Knowing that drug resistance is very common in patients treated with TKI, it is important to be able to measure drug response in different mutants, for the selection of the most appropriate inhibitor. Due to NAPPA's nature, the screening of kinase mutants is simple and can be easily accomplished, and the only required tool is the incorporation of the kinase mutant into the NAPPA cDNA collection, which can be done by site-specific mutagenesis, for instance.
Future applications
One of the most common forms of treatment elapse in cancer therapy using kinase inhibitors is the acquisition of mutations in the drug target during a treatment course. The screening of these mutants regarding their response to kinase inhibitors is of vital importance for the selection of second/third generation of TKIs to achieve a personalized treatment for each patient. The drug screening approach presented here, provides an unbiased screening platform in which any tyrosine kinase inhibitor can be tested against a panel of tyrosine kinases present in the human genome. Since the proteins displayed on NAPPA arrays are expressed in vitro from the cDNA printed on the slide, any mutant variant can easily be incorporated in the cDNA collection to be displayed on the array. The facility in which the kinase mutants can be generated and expressed on the array, combined with the high-throughput power of the NAPPA technique, provides a unique environment for the study of kinase mutants and their response to drugs, making NAPPA suitable for personalized drug screening, one of the goals of precision medicine.
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